GAITHERSBURG, Maryland — Boston Scientific (BSX; Natick, Massachusetts) scored a resounding 13-1 victory in the second advisory panel for the Watchman left atrial appendage closure device in a hearing that drew 10 respondents for the open public hearing. The vote came with a strong recommendation for a heftier post-approval study recommendation than the firm had proposed, which was a single-arm, five-year study of 1,000 existing and new patients. The big question is whether the company will have to foot the bill for a post-approval study and participate in the build-out of a registry. Read More
